摘要
目的观察NP化疗方案联合唑来膦酸治疗非小细胞肺癌(NSCLC)骨转移的疗效。方法把60例骨转移的NSCLC患者随机分为两组,每组30例。治疗组接受唑来膦酸联合NP方案化疗,对照组为单纯NP方案化疗。结果治疗组疼痛缓解率83.3%,对照组56.7%(X2=9.00,P=0.024);骨病灶控制总有效率,治疗组为53.3%,对照组为20.0%(X2=11.00,P=0.007)。两组均无明显的不良反应。结论唑来膦酸联合NP方案化疗对NSCLC骨转移有较好的治疗作用。
Objective Toinvestigate the response rate of chemotherapy combined Zoledronic Acid on Patients with NSCLC Bone Metastasis.Methods 60 patients with NSCLC bone metastatis were divivded randanly into tow groups.30 patients received Zoledronic acid combined NP chemotherapy, 30 patients only received NP chemotherapy.Results Response rate of bone painrelief was 83.3% in Zoledronic acid combined NP chemotherapeutic group and 56.7% in chemotherapy alone group.Response rate of bone metastases was 53.3% in Zoledronic acid combined NP chemotherapeutic group and 20% in chemotherapy alone group.No serious side effect were found in both groups.Conclusion Zoledronic acid is safe, well tolerated and very effective treatment for patients with Lung cancer bone metastasis.It can be widely used.
